抄録
Since 1980, 184 patients with central lung cancers, including 48 cases of endoscopically evaluated early-stage lesions have been treated with PDT at Tokyo Medical College, and CR rate of 77% was achieved for early-stage lesion. However, wider clinical application of Photofrin II as a photosensitizer for various cancer is hampered by the potentially serious and prolonged skin photosensitivity that can last for three weeks or more. In those patients who did not heed recommendations to avoid sunlight and use sunscreens. 90% of patients had skin photosensitivity with currently recommended doses of Photofrin II (2mg/kg) in our experience.
To prevent those side effects and reduce the impatient period, we recently tried to give reduce doses of Photofrin II by BAI. Five patients with endoscopically evaluated early-stage carcinoma and two with advanced carcinoma of the lung were given 0.7mg/kg of Photofrin II by BAI 48 hours before PDT.
Complete response was obtained in all early-stage cases and those was no evidence of skin photosensitivity when exposed to outside light under surveillance at one week after PDT.
